Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 5:35 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 94 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Psychotic Episode Clear all
Completed No phase listed Observational Accepts healthy volunteers Results available

Feasibility of an Early Detection Program for Early Psychosis on a College Campus

NCT03983421
View directory record Official record
Conditions
Psychosis, First Episode Psychosis, Clinical High Risk for Psychosis
Interventions
Not listed
Lead sponsor
University of New Mexico
Other
Eligibility
15 Years to 30 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Mar 31, 2024 · Synced Sep 3, 2026, 5:35 PM EDT
Completed Phase 3 Interventional Results available

Monotherapy Brexpiprazole (OPC-34712) Trial in the Treatment of Adults With Early-Episode Schizophrenia

NCT02013622
View directory record Official record
Conditions
Schizophrenia
Interventions
Brexpiprazole
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 35 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
22
States / cities
Cerritos, California • Chula Vista, California • Costa Mesa, California + 17 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2016 · Synced Sep 3, 2026, 5:35 PM EDT
Active, not recruiting Early Phase 1 Interventional

Trial to Increase FEP Attendance

NCT05967195
View directory record Official record
Conditions
First-Episode Psychosis
Interventions
Financial Incentive and Text-Messages
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
3
States / cities
Raleigh, North Carolina • Philadelphia, Pennsylvania • Philadephia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 10, 2026 · Synced Sep 3, 2026, 5:35 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Psychosocial Therapy and Risperidone Treatment in Work Performance in Recent-Onset Schizophrenia

NCT00333177
View directory record Official record
Conditions
Schizophrenia
Interventions
Cognitive remediation training (CT), Healthy behavior training (HBT), Risperidone, administered orally (Oral Ris), Risperidone, administered via injection (RLAI)
Behavioral · Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 45 Years
Enrollment
92 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2013
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 25, 2020 · Synced Sep 3, 2026, 5:35 PM EDT
Recruiting Not applicable Interventional

Digital Strategies to Advance Help-Seeking - Aim 3

NCT06774417
View directory record Official record
Conditions
Clinical High Risk, Early Psychosis, First Episode Psychosis
Interventions
Digital nudge
Other
Lead sponsor
Columbia University
Other
Eligibility
12 Years to 29 Years
Enrollment
25,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Sep 3, 2026, 5:35 PM EDT
Terminated Phase 4 Interventional Results available

Optimizing Response in Psychosis Study

NCT00314327
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Psychotic Disorder Not Otherwise Specified
Interventions
long-acting injectable risperidone
Drug
Lead sponsor
Northwell Health
Other
Eligibility
15 Years to 40 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
2
States / cities
Brooklyn, New York • Glen Oaks, New York
Source: ClinicalTrials.gov public record
Updated May 15, 2018 · Synced Sep 3, 2026, 5:35 PM EDT
Completed Phase 3 Interventional

CAFE Comparison of Atypicals in First Episode of Psychosis

NCT00034892
View directory record Official record
Conditions
Schizophrenia, Psychotic Disorders, Mental Health, Mental Disorders
Interventions
Olanzapine, risperidone
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
16 Years to 40 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
24
States / cities
Stanford, California • Miami, Florida • Atlanta, Georgia + 21 more
Source: ClinicalTrials.gov public record
Updated Jan 3, 2013 · Synced Sep 3, 2026, 5:35 PM EDT
Recruiting No phase listed Observational

Transition Care for FEP

NCT07713849
View directory record Official record
Conditions
Schizoaffective Disorders, Bipolar Disorder With Psychotic Features, Schizophrenia Disorders, Major Depressive Disorder With Psychotic Features, Psychosis NOS
Interventions
Transition Care Team
Behavioral
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 40 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
2
States / cities
Chicago, Illinois • Harvey, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 19, 2026 · Synced Sep 3, 2026, 5:35 PM EDT
Completed Not applicable Interventional

Graduated Recovery Intervention Program for Enhancing Treatment for First-Episode Psychosis

NCT00307216
View directory record Official record
Conditions
Psychotic Disorders, Schizophrenia
Interventions
Graduated Recovery Intervention Program (GRIP), Treatment as usual (TAU)
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 28, 2013 · Synced Sep 3, 2026, 5:35 PM EDT
Terminated Phase 4 Interventional Results available

Aripiprazole Lauroxil for Preventing Psychotic Relapse After an Initial Schizophrenia Episode

NCT04203056
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Depressive Type, Schizophreniform Disorder
Interventions
Aripiprazole Lauroxil, ARI-ORAL, AL-NCD
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 45 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 27, 2023 · Synced Sep 3, 2026, 5:35 PM EDT
Recruiting Not applicable Interventional

Improving Cognition Through Telehealth Aerobic Exercise and Cognitive Training After a First Schizophrenia Episode

NCT05890183
View directory record Official record
Conditions
Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder
Interventions
Cognitive training, Aerobic Exercise Program, Moderated Online Social Therapy (MOST), Chorus Participatory Text Messaging Program, Healthy Living Group (HLG)
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 45 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Sep 3, 2026, 5:35 PM EDT
Completed Phase 3 Interventional Results available

Aripiprazole in Children and Adolescents With Bipolar I Disorder

NCT00110461
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Aripiprazole, placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
10 Years to 17 Years
Enrollment
296 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
53
States / cities
Scottsdale, Arizona • Little Rock, Arkansas • National City, California + 50 more
Source: ClinicalTrials.gov public record
Updated May 20, 2012 · Synced Sep 3, 2026, 5:35 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Oral Risperidone Versus Injectable Paliperidone Palmitate for Treating First-Episode Schizophrenia

NCT01451736
View directory record Official record
Conditions
Schizophrenia (Recent-onset)
Interventions
paliperidone palmitate, risperidone
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 45 Years
Enrollment
146 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2021
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 10, 2022 · Synced Sep 3, 2026, 5:35 PM EDT
Enrolling by invitation Not applicable Interventional

Reducing the Duration of Untreated Psychosis in the United States: The Impact of Screening and Systematic Communication

NCT05509998
View directory record Official record
Conditions
First Episode Psychosis (FEP), Clinical High Risk for Psychosis (CHR)
Interventions
Screening Method (SM), Screening and Communication Method (SCM)
Behavioral
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
12 Years to 30 Years
Enrollment
912 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 19, 2025 · Synced Sep 3, 2026, 5:35 PM EDT
Terminated Not applicable Interventional Results available

Horyzons: Implementation and Integration in Clinical Practice

NCT06002958
View directory record Official record
Conditions
Schizophrenia, Schizophreniform Disorders, Schizoaffective Disorder, Unspecified or Other Psychotic Disorders
Interventions
Horyzons USA
Device
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
16 Years to 35 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 17, 2025 · Synced Sep 3, 2026, 5:35 PM EDT
Recruiting Not applicable Interventional

Normobaric Oxygen Therapy for Individuals With First-Episode Psychosis

NCT04368039
View directory record Official record
Conditions
Psychosis, Schizophrenia, First-episode Psychosis
Interventions
Normobaric Oxygen, Placebo
Device
Lead sponsor
Nicholas Breitborde
Other
Eligibility
15 Years to 35 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Sep 3, 2026, 5:35 PM EDT
Completed Not applicable Interventional

Integrated Coping and Awareness Training

NCT02400502
View directory record Official record
Conditions
Schizophrenia
Interventions
I-CAT Therapy
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 35 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 7, 2016 · Synced Sep 3, 2026, 5:35 PM EDT
Completed Not applicable Interventional Results available

Minnesota Community-Based Cognitive Training in Early Psychosis

NCT03079024
View directory record Official record
Conditions
Schizophrenia, Psychosis, Schizoaffective Disorder, Schizophreniform Disorders, Psychosis NOS, Depression Psychotic Feature, Bipolar Disorder With Psychotic Features, Unspecified Psychosis
Interventions
Targeted Cognitive Training, General Cognitive Exercises, Coordinated Specialty Care for First Episode Psychosis
Device · Other
Lead sponsor
University of Minnesota
Other
Eligibility
16 Years to 35 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 22, 2025 · Synced Sep 3, 2026, 5:35 PM EDT
Completed Not applicable Interventional

Using mHealth to Optimize Pharmacotherapy Regimens

NCT04248517
View directory record Official record
Conditions
Schizophrenia, First-Episode Psychosis
Interventions
mHealth Intervention
Other
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
16 Years to 30 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
4
States / cities
Buffalo, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 12, 2026 · Synced Sep 3, 2026, 5:35 PM EDT
Enrolling by invitation Not applicable Interventional

Open Label Extension Study of NCT06221852

NCT06558201
View directory record Official record
Conditions
Bipolar I Disorder, Schizoaffective Disorder, Psychosis
Interventions
Ketogenic diet
Other
Lead sponsor
Mclean Hospital
Other
Eligibility
18 Years to 45 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 16, 2026 · Synced Sep 3, 2026, 5:35 PM EDT
Terminated Phase 3 Interventional Results available

Safety and Tolerability of Aripiprazole in Adolescents With Schizophrenia or Children and Adolescents With Bipolar I Disorder, Manic or Mixed Episode With or Without Psychotic Features.

NCT01122927
View directory record Official record
Conditions
Adolescent Schizophrenia, Child or Adolescent Bipolar I Disorder, Manic or Mixed Episode With or Without Psychotic Features
Interventions
Aripiprazole
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
10 Years to 17 Years
Enrollment
524 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
23
States / cities
Dothan, Alabama • Downey, California • Miami, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2016 · Synced Sep 3, 2026, 5:35 PM EDT
Completed Phase 4 Interventional Results available

Comparison of a Long-acting Injectable Antipsychotic vs Clinician's Choice Early in Treatment to Break the Cycle of Relapse in Early Phase Schizophrenics

NCT02360319
View directory record Official record
Conditions
Schizophrenia
Interventions
Any FDA approved antipsychotic agent, aripiprazole long acting injectable formulation
Drug
Lead sponsor
Vanguard Research Group
Other
Eligibility
18 Years to 35 Years
Enrollment
489 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
39
States / cities
Tucson, Arizona • Granada Hills, California • Palo Alto, California + 35 more
Source: ClinicalTrials.gov public record
Updated Dec 1, 2020 · Synced Sep 3, 2026, 5:35 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

OnTrack>An Online Role-Playing Game for Young People With First Episode Psychosis

NCT03390491
View directory record Official record
Conditions
Psychosis, Schizoaffective Disorder, Schizophrenia
Interventions
OnTrack>TheGame (OTG), Recovery Videos (RV)
Behavioral
Lead sponsor
Center for Social Innovation, Massachusetts
Other
Eligibility
16 Years to 30 Years
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 25, 2021 · Synced Sep 3, 2026, 5:35 PM EDT
Withdrawn Not applicable Interventional

OnTrackNY With the Option of Social Network Meetings

NCT03464162
View directory record Official record
Conditions
First Episode Psychosis, Schizophrenia
Interventions
Social Network Meetings
Behavioral
Lead sponsor
Lisa Dixon
Other
Eligibility
16 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Yonkers, New York
Source: ClinicalTrials.gov public record
Updated Aug 13, 2023 · Synced Sep 3, 2026, 5:35 PM EDT